A high-throughput single-particle imaging platform for antibody characterization and a novel competition assay for therapeutic antibodies

• Published in: Scientific reports Vol. 13; no. 1; p. 306
• Main Authors: Seymour, Elif, Ünlü, M. Selim, Connor, John H.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 06.01.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 631/326; 631/61/32; 639/166/985; 692/699/255; Animal models; Animals; Antibodies; Antibodies, Neutralizing; Antibodies, Viral; Competition; Ebolavirus; Epitope mapping; Epitopes; Glycoproteins; Hemorrhagic Fever, Ebola; High-throughput screening; Humanities and Social Sciences; Immunologic Factors - metabolism; Infectious diseases; Monoclonal antibodies; multidisciplinary; Science; Science (multidisciplinary); Stomatitis; Viruses
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-27281-w

Monoclonal antibodies (mAbs) play an important role in diagnostics and therapy of infectious diseases. Here we utilize a single-particle interferometric reflectance imaging sensor (SP-IRIS) for screening 30 mAbs against Ebola, Sudan, and Lassa viruses (EBOV, SUDV, and LASV) to find out the ideal capture antibodies for whole virus detection using recombinant vesicular stomatitis virus (rVSV) models expressing surface glycoproteins (GPs) of EBOV, SUDV, and LASV. We also make use of the binding properties on SP-IRIS to develop a model for mapping the antibody epitopes on the GP structure. mAbs that bind to mucin-like domain or glycan cap of the EBOV surface GP show the highest signal on SP-IRIS, followed by mAbs that target the GP1-GP2 interface at the base domain. These antibodies were shown to be highly efficacious against EBOV infection in non-human primates in previous studies. For LASV detection, 8.9F antibody showed the best performance on SP-IRIS. This antibody binds to a unique region on the surface GP compared to other 15 mAbs tested. In addition, we demonstrate a novel antibody competition assay using SP-IRIS and rVSV-EBOV models to reveal the competition between mAbs in three successful therapeutic mAb cocktails against EBOV infection. We provide an explanation as to why ZMapp cocktail has higher efficacy compared to the other two cocktails by showing that three mAbs in this cocktail (13C6, 2G4, 4G7) do not compete with each other for binding to EBOV GP. In fact, the binding of 13C6 enhances the binding of 2G4 and 4G7 antibodies. Our results establish SP-IRIS as a versatile tool that can provide high-throughput screening of mAbs, multiplexed and sensitive detection of viruses, and evaluation of therapeutic antibody cocktails.